Clinical Trial

Home Monitoring in eAMD Treatment

Study acronym: HOME

Not Yet Recruiting

Summary

The goal of this observational clinical study is to collect more information about the efficacy of Aflibercept 8 mg injections in people with eAMD. The main questions it aims to answer are: * To reassure patients and doctors with longer intervals using home monitoring app; * To assess patient reported outcomes (PROMs) and Value-based Healthcare. Participants already taking Aflibercept 8 mg as part of their regular medical care for eAMD will undergo regular ophthalmological examination and use a home monitoring app, in a one year and a two-year treatment period.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2026-01-06; most recent amendment 2026-05-05.

Trial Details

NCT Number	NCT07340372
Lead Sponsor	Association for Innovation and Biomedical Research on Light and Image
Conditions	Exudative Age-Related Macular Degeneration
Enrollment	80 participants
Start Date	2026-05
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-06